Volume 14, Number 8—August 2008
Dispatch
Oseltamivir Prescribing in Pharmacy-Benefits Database, United States, 2004–20051
Justin R. Ortiz*2
, Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†
, Laurie Kamimoto*, Ronald E. Aubert†, Jianying Yao†, David K. Shay*, Joseph S. Bresee*, and Robert S. Epstein†Table 2
Oseltamivir prescription rates/100,000 enrollees by age and chronic disease classification, United States, weeks 36–44, 2004 and 2005
| Characteristic | 2004 | 2005 | Rate ratio (2005/2004) | 95% Confidence interval |
|---|---|---|---|---|
| Age group, y | ||||
| <1 | 0.26 | 10.65 | 40.7 | (5.6–294) |
| 1–4 | 8.95 | 65.95 | 7.4 | (6.3–8.6) |
| 5–17 | 11.12 | 81.28 | 7.3 | (6.8–7.9) |
| 18–24 | 19.55 | 81.42 | 4.2 | (3.8–4.5) |
| 25–49 | 33.08 | 120.97 | 3.7 | (3.5–3.8) |
| 50–64 | 63.33 | 211.26 | 3.3 | (3.2–3.4) |
| >65 |
69.04 |
168.20 |
2.4 |
(2.4–2.5) |
| Chronic disease classification* | ||||
| Pulmonary | 77.66 | 268.50 | 3.46 | (3.33–3.60) |
| Immune deficient | 67.75 | 240.16 | 3.54 | (3.21–3.91) |
| Neurologic | 54.57 | 207.43 | 3.80 | (3.47–4.15) |
| Cardiac | 54.11 | 196.92 | 3.64 | (3.54–3.74) |
| Diabetes | 50.85 | 143.85 | 2.83 | (2.64–3.02) |
| Chronic disease absent |
14.07 |
89.50 |
6.36 |
(6.10–6.62) |
| *Rates from chronic disease classification include only enrollees >18 y of age. Except for the chronic disease absent category, all chronic disease classifications were not mutually exclusive. Chronic disease classification is derived from the chronic disease index, which has been validated (10). | ||||
1This study was presented, in part, at the Infectious Diseases Society of America annual meeting in Toronto, Ontario, Canada, October 14, 2006, and in poster form at the Options for the Control of Influenza Conference, Toronto, June 17, 2007.
2Current affiliation: University of Washington, Seattle, WA, USA.
